46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
September 2021 in “Journal of the American Academy of Dermatology” CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
1 citations
,
November 2018 in “immuneACCESS” Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
May 2023 in “The Journal of Immunology” Alopecia areata involves unique activation of certain immune cells.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
October 1984 in “Immunology Today” Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.
5 citations
,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
Dual TCR Treg cells are common in mouse tissues and vary by location.
July 2024 in “Journal of Investigative Dermatology” Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
441 citations
,
May 1996 in “Journal of Cell Science” Keratin 19 helps identify skin stem cells, with its presence varying by body location, age, and culture stage.
April 2023 in “Journal of Investigative Dermatology” Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
2 citations
,
March 2010 in “Acta Biochimica Polonica” Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.
January 2026 in “Human Mutation” T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
1 citations
,
May 2016 in “Journal of Cosmetic Dermatology” Cytokeratins 15 and 19 may help track vitiligo treatment progress.
May 2023 in “The Journal of Immunology” Expanding CD4+ Tregs can stop hair loss in alopecia areata.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
30 citations
,
July 2019 in “PloS one” Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.
January 2012 in “heiDOK (Heidelberg University)” Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
January 2011 in “Repository KITopen (Karlsruhe Institute of Technology)” Blocking certain proteins on immune cells may help treat alopecia areata.
43 citations
,
August 1994 in “Journal of Investigative Dermatology”
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.